Skip to main content
SpringerLink
Log in
Book cover

Multiplex Biomarker Techniques pp 19–35Cite as

The Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1546))

Abstract

In the case of major psychiatric disorders such as schizophrenia, shortcomings in the conversion of scientific discoveries into newer and safer treatment options has led to a loss of confidence and precipitated a crisis for large pharmaceutical companies. This chapter describes how incorporation of multiplex biomarker approaches into the clinical pipeline can lead to better patient characterization, delivery of novel treatment approaches and help to renew efforts in this important area. The development of specific biomarker test panels for disease prediction should facilitate early intervention strategies, which may help to slow disease development or progression. Furthermore, the development of such tests using lab-on-a-chip and smartphone platforms will help to shift diagnosis and treatment of this major disorder into a point-of-care setting for improved patient outcomes.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645

    PubMed  Google Scholar 

  2. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Publishing, Arlington, VA. ISBN 10: 0890425558

    Google Scholar 

  3. World Health Organization (1 Jan. 1992) ICD-10: The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organisation. ISBN-10: 9241544228

    Google Scholar 

  4. Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J (2014) Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205:88–94

    PubMed  Google Scholar 

  5. Jablensky A (2000) Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 250:274–285

    CAS  PubMed  Google Scholar 

  6. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:1575–1586

    PubMed  Google Scholar 

  7. Liu Y, Dalal K, Stollenwerk B (2013) The association between health system development and the burden of cardiovascular disease: an analysis of WHO country profiles. PLoS One 8:e61718

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Tsuang MT (1975) Heterogeneity of schizophrenia. Biol Psychiatry 10:465–474

    CAS  PubMed  Google Scholar 

  9. Gonzalez-Pinto A, Gutierrez M, Mosquera F, Ballesteros J, Lopez P, Ezcurra J et al. (1998) First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord 50:41–44

    CAS  PubMed  Google Scholar 

  10. Follette WC, Houts AC (1996) Models of scientific progress and the role of theory in taxonomy development: a case study of the DSM. J Consult Clin Psychol 64:1120–1132

    CAS  PubMed  Google Scholar 

  11. Yolken RH, Dickerson FB, Fuller TE (2009) Toxoplasma and schizophrenia. Parasite Immunol 31:706–715

    CAS  PubMed  Google Scholar 

  12. Lovatt A, Mason O, Brett C, Peters E (2010) Psychotic-like experiences, appraisals, and trauma. J Nerv Ment Dis 198:813–819

    PubMed  Google Scholar 

  13. Clayton PJ, Guze SB, Cloninger CR, Martin RL (1992) Unipolar depression: diagnostic inconsistency and its implications. J Affect Disord 26:111–116

    CAS  PubMed  Google Scholar 

  14. Bromet EJ, Kotov R, Fochtmann LJ, Carlson GA, Tanenberg-Karant M, Ruggero C et al. (2011) Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 168:1186–1194

    PubMed  PubMed Central  Google Scholar 

  15. Torrey EF (1992) Are we overestimating the genetic contribution to schizophrenia? Schizophr Bull 18:159–170

    CAS  PubMed  Google Scholar 

  16. McGue M (1992) When assessing twin concordance, use the probandwise not the pairwise rate. Schizophr Bull 18:171–176

    CAS  PubMed  Google Scholar 

  17. Tsuang M (2000) Schizophrenia: genes and environment. Biol Psychiatry 47:210–220

    CAS  PubMed  Google Scholar 

  18. Dauncey MJ, Bicknell RJ (1999) Nutrition and neurodevelopment: mechanisms of developmental dysfunction and disease in later life. Nutr Res Rev 12:231–253

    CAS  PubMed  Google Scholar 

  19. Schlotz W, Phillips DI (2009) Fetal origins of mental health: evidence and mechanisms. Brain Behav Immun 23:905–916

    PubMed  Google Scholar 

  20. Koenig JI, Kirkpatrick B, Lee P (2002) Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology 27:309–318

    CAS  PubMed  Google Scholar 

  21. Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–489

    PubMed  Google Scholar 

  22. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24:481–445

    CAS  PubMed  Google Scholar 

  23. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A et al. (2010) Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15:118–119

    Google Scholar 

  24. Szulc A, Galińska B, Konarzewska B, Gudel-Trochimowicz I, Popławska R (2001) Immunological marker activity in first episode schizophrenic patients. Pol Merkur Lekarski 10:450–452

    CAS  PubMed  Google Scholar 

  25. Van Venrooij JA, Fluitman SB, Lijmer JG, Kavelaars A, Heijnen CJ, Westenberg HG et al. (2012) Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr Bull 38:272–279

    Google Scholar 

  26. Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD et al. (2014) Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull 41:419–428

    Google Scholar 

  27. Chan MK, Krebs MO, Cox D, Guest PC, Yolken RH, Rahmoune H et al. (2015) Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl Psychiatry 5, e601. doi:10.1038/tp.2015.91

  28. Agius M, Shah S, Ramkisson R, Murphy S, Zaman R (2007) Three year outcomes of an early intervention for psychosis service as compared with treatment as usual for first psychotic episodes in a standard community mental health team. Preliminary results. Psychiatr Danub 19:10–19

    PubMed  Google Scholar 

  29. Salokangas RK, McGlashan TH (2008) Early detection and intervention of psychosis. A review. Nord J Psychiatry 62:92–105

    PubMed  Google Scholar 

  30. Yap HL (2010) Early psychosis intervention. Singapore Med J 51:689–693

    CAS  PubMed  Google Scholar 

  31. Thomas P (2004) The many forms of bipolar disorder: a modern look at an old illness. J Affect Disord 79(Suppl 1):S3–S8

    PubMed  Google Scholar 

  32. Hirschfeld RM (2001) Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiatry 62(Suppl 14):5–9

    PubMed  Google Scholar 

  33. Post RM (2005) The impact of bipolar depression. J Clin Psychiatry 66(Suppl 5):5–10

    PubMed  Google Scholar 

  34. Kamel N, Compton C, Middelveld R, Higenbottam T, Dahlén SE (2008) The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level. Eur Respir J 31:924–926

    CAS  PubMed  Google Scholar 

  35. Hunter AJ (2008) The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov Today 13:371–373

    PubMed  Google Scholar 

  36. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm124105.ht

  37. Ellington AA, Kullo IJ, Bailey KR, Klee GG (2010) Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 56:186–193

    Google Scholar 

  38. Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H et al. (2009) Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 14:1069–1071

    Google Scholar 

  39. Merrill JE (1992) Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14:1–10

    CAS  PubMed  Google Scholar 

  40. Meyer U, Feldon J, Yee BK (2009) A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 35:959–972

    PubMed  Google Scholar 

  41. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E (2007) Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7:46

    PubMed  PubMed Central  Google Scholar 

  42. Schmitt A, Leonardi-Essmann F, Durrenberger PF, Parlapani E, Schneider-Axmann T, Spanagel R et al. (2011) Regulation of immunemodulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World J Biol Psychiatry 12:201–215

    Google Scholar 

  43. Montejo AL (2010) The need for routine physical health care in schizophrenia. Eur Psychiatry 25(Suppl 2):S3–S5

    PubMed  Google Scholar 

  44. Pedrini M, Massuda R, Fries GR, de BittencourtPasquali MA, Schnorr CE, Moreira JC, et al. (2012) Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 46:819–824

    Google Scholar 

  45. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC et al. (2010) Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 5:39–47

    Google Scholar 

  47. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. (2012) Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 17: 494–502

    Google Scholar 

  48. Späth-Schwalbe E, Born J, Schrezenmeier H, Bornstein SR, Stromeyer P, Drechsler S et al. (1994) Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 79:1212–1214

    PubMed  Google Scholar 

  49. Straub RH, Buttgereit F, Cutolo M (2011) Alterations of the hypothalamic-pituitaryadrenal axis in systemic immune diseases – a role for misguided energy regulation. Clin Exp Rheumatol 29:S23–S31

    CAS  PubMed  Google Scholar 

  50. Bremner JD (2006) Traumatic stress: effects on the brain. Dialogues Clin Neurosci 8:445–461

    PubMed  PubMed Central  Google Scholar 

  51. Spijker AT, van Rossum EF (2012) Glucocorticoid sensitivity in mood disorders. Neuroendocrinology 95:179–186

    CAS  PubMed  Google Scholar 

  52. Müller N, Riedel M, Schwarz MJ (2004) Psychotropic effects of COX-2 inhibitors – a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 37:266–269

    PubMed  Google Scholar 

  53. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B (2007) Celecoxib as adjunctive therapy in schizophrenia: a doubleblind, randomized and placebo-controlled trial. Schizophr Res 90:179–185

    PubMed  Google Scholar 

  54. Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M et al. (2010) Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebocontrolled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 121:118–124

    Google Scholar 

  55. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:520–527

    CAS  PubMed  Google Scholar 

  56. Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM et al (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first episode schizophrenia patients. J Clin Psychiatry 65:1335–1342

    Google Scholar 

  57. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 51:382–386

    PubMed  Google Scholar 

  58. van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L et al (2008) Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 93:572–577

    PubMed  Google Scholar 

  59. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011(36):1092–1096

    Google Scholar 

  60. Taguchi A, Wartschow LM, White MF (2007) Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317:369–372

    CAS  PubMed  Google Scholar 

  61. Convit A (2005) Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 26(Suppl 1):31–35

    PubMed  Google Scholar 

  62. Craft S (2007) Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4:147–152

    CAS  PubMed  Google Scholar 

  63. Bello NT, Hajnal A (2006) Alterations in blood glucose levels under hyperinsulinemia affect accumbens dopamine. Physiol Behav 2006(88):138–145

    Google Scholar 

  64. O’Malley D, Shanley LJ, Harvey J (2003) Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+-activated K+ channels. Neuropharmacology 44:855–863

    PubMed  Google Scholar 

  65. Corcoran CM, Smith C, McLaughlin D, Auther A, Malaspina D, Cornblatt B (2012) HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr Res 135:170–174

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Gorobets LN, Matrosova MI (2010) Specialties of prolactin secretion and peripheral reproductive sex hormones in patients with of first episode of schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova 110:17–22

    CAS  PubMed  Google Scholar 

  67. Akiibinu MO, Ogundahunsi OA, Ogunyemi EO (2012) Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes 5:169

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 17:110–116

    CAS  PubMed  Google Scholar 

  69. Tannenbaum GS, Martin JB, Colle E (1976) Ultradian growth hormone rhythm in the rat: effects of feeding, hyperglycemia, and insulin-induced hypoglycemia. Endocrinology 99:720–727

    CAS  PubMed  Google Scholar 

  70. Meltzer HY, Perry E, Jayathilake K (2003) Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 59:19–27

    PubMed  Google Scholar 

  71. Bahtiyar G, Weiss K, Sacerdote AS (2007) Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocr Pract 13:601–608

    PubMed  Google Scholar 

  72. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPARgamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32:1626–1633

    CAS  PubMed  Google Scholar 

  73. Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R et al (2005) Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res 79:251–256

    PubMed  Google Scholar 

  74. Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M et al (2011) Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 72:1552–1557

    CAS  PubMed  Google Scholar 

  75. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615–1616

    CAS  PubMed  Google Scholar 

  76. Zhang JP, Malhotra AK (2011) Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 7:9–37

    PubMed  PubMed Central  Google Scholar 

  77. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC et al (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43:620–626. doi:10.1016/j.jpsychires.2008.11.001, Epub 2008 Dec 24

    Article  PubMed  Google Scholar 

  78. Lau SL, Muir C, Assur Y, Beach R, Tran B, Bartrop R et al (2016) Predicting weight gain in patients treated with clozapine: the role of sex, body mass index, and smoking. J Clin Psychopharmacol 36:120–124

    CAS  PubMed  Google Scholar 

  79. Shrivastava A, Johnston M, Bureau Y, Shah N (2012) Baseline serum prolactin in drug naive, first-episode schizophrenia and outcome at five years: is it a predictive factor? Innov Clin Neurosci 2012(9):17–21

    Google Scholar 

  80. Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S (2012) Identification of blood based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry 2, e82

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Schwarz E, Steiner J, Guest PC, Bogerts B, Bahn S (2015) Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. World J Biol Psychiatry 16:22–30

    PubMed  Google Scholar 

  82. Tomasik J, Schwarz E, Lago SG, Rothermundt M, Leweke FM, van Beveren NJ et al (2016) Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain Behav Immun 52:178–186

    CAS  PubMed  Google Scholar 

  83. Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A et al (2010) Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 5(2):e9166

    PubMed  PubMed Central  Google Scholar 

  84. Salmon SE, Mackey G, Fudenberg HH (1969) “Sandwich” solid phase radioimmunoassay for the quantitative deterimination of human immunoglobulins. J Immunol 103:129–137

    CAS  PubMed  Google Scholar 

  85. Salmon SE, Smith BA (1970) Sandwich solid phase radioimmunoassays for the characterization of human immunoglobulins synthesized in vitro. J Immunol 104:665–672

    CAS  PubMed  Google Scholar 

  86. Schumacher S, Nestler J, Otto T, Wegener M, Ehrentreich-Förster E, Michel D et al (2012) Highly-integrated lab-on-chip system for point-of-care multiparameter analysis. Lab Chip 12:464–473

    CAS  PubMed  Google Scholar 

  87. Krishna S, Boren SA, Balas EA (2009) Healthcare via cell phones: a systematic review. Telemed J E Health 15:231–240

    PubMed  Google Scholar 

  88. Berg B, Cortazar B, Tseng D, Ozkan H, Feng S, Wei Q et al (2015) Cellphone-based hand-held micro-plate reader for point-of-care testing of enzyme-linked immunosorbent assays. ACS Nano 9:7857–7866

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

D.M.S. and the Laboratory of Neuroproteomics, UNICAMP are funded by FAPESP (São Paulo Research Foundation) grant number 13/08711-3.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany

    Johann Steiner

  2. Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Rua Monteiro Lobato 255, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, Brazil

    Paul C. Guest

  3. Department of Chemical Engineering and Biotechnology, University of Cambridge, Pembroke Street, Cambridge, UK

    Hassan Rahmoune

  4. Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Rua Monteiro Lobato 255, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, SP, Brazil

    Daniel Martins-de-Souza

Authors
  1. Johann Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul C. Guest
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hassan Rahmoune
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Martins-de-Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johann Steiner .

Editor information

Editors and Affiliations

  1. Laboratory of Neuroproteomics, University of Campinas (UNICAMP), Campinas, Brazil

    Paul C. Guest

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Steiner, J., Guest, P.C., Rahmoune, H., Martins-de-Souza, D. (2017). The Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients. In: Guest, P.C. (eds) Multiplex Biomarker Techniques. Methods in Molecular Biology, vol 1546. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-6730-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6730-8_2

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-6729-2

  • Online ISBN: 978-1-4939-6730-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation